Methotrexat Sandoz (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize purine and pyrimidine nucleotides, leading to impaired DNA, RNA and protein production. This antiproliferative effect reduces immune cell activity and halts the growth of rapidly dividing cancer cells.

The exact dose of Methotrexat Sandoz is set by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. Dosage regimens vary widely between autoimmune disorders and oncology protocols, and adjustments are made according to laboratory monitoring and clinical response.

Methotrexat Sandoz is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Methotrexat Sandoz. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexat Sandoz shares the core mechanism of dihydrofolate reductase inhibition with other antimetabolites such as pemetrexed, but it differs in its approved indications and dosing routes. Compared with newer agents, methotrexate has a long‑established safety profile, broader use in both rheumatology and oncology, and is generally less expensive.

Methotrexat Sandoz should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not store at room temperature for extended periods, as stability may be compromised.

The product is supplied as an injectable solution and may be given via intra‑arterial, intramuscular, or intrathecal routes. Administration is performed by a qualified healthcare professional under aseptic conditions, with dosing intervals and volumes determined by the treating physician based on the therapeutic indication.

The most critical adverse events include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity that can progress to fibrosis or cirrhosis, and pulmonary toxicity such as interstitial pneumonitis. Early detection through regular blood counts, liver function tests and respiratory assessment is essential to mitigate these risks.

Methotrexat Sandoz is contraindicated in pregnant women, nursing mothers, and patients with known hypersensitivity to methotrexate or its excipients. It should also be avoided in individuals with severe renal or hepatic impairment, uncontrolled infections, or those receiving live vaccines, unless a specialist determines the benefits outweigh the risks.